MW Advisory’s Moderna MRNA Stock Holding History

MW Advisory’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$278K	Buy	+1,444	New	+$156K	0.11%	107

Other funds holding MRNA

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

Beau Ventures, LLc Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

LAI

Legal Advantage Investments Los Altos Hills, California $468M AUM 7.83% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

MW Advisory's MRNA Position: Q3 2026 in Review

MW Advisory opened a new position in Moderna (MRNA) in Q3 2026: 1,444 shares worth $278K. The stake represents 0.11% of the portfolio and ranks #107 among its holdings.

221 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

MW Advisory held 1,444 shares of Moderna worth $278K as of Q3 2026.
Moderna was a new MW Advisory position in Q3 2026.
Moderna made up 0.11% of MW Advisory's portfolio in Q3 2026, its #107 holding.
221 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on MW Advisory's 13F filing for Q3 2026, filed 19 Oct 2026.